We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cobra Biologics Receives the Queen’s Award for Enterprise in International Trade
Product News

Cobra Biologics Receives the Queen’s Award for Enterprise in International Trade

Cobra Biologics Receives the Queen’s Award for Enterprise in International Trade
Product News

Cobra Biologics Receives the Queen’s Award for Enterprise in International Trade

Cobra Centre of Excellence, UK

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Cobra Biologics Receives the Queen’s Award for Enterprise in International Trade"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cobra Biologics a leading international contract development and manufacturing organisation announced that it has been awarded the Queen’s Award 2018 for Enterprise, in the International Trade category. The prestigious award is in recognition of Cobra’s commercial success in providing services to its global customer base.

Now in their 53rd year, the Queen’s Awards have a long history of recognising exceptional UK businesses and Cobra will be attending a reception at Buckingham Palace followed by a presentation of the Award by a representative of Her Majesty The Queen at Cobra’s UK facility later in the year.

Cobra has a 20 year track record of supporting the life science industry with contract development and manufacturing of biopharmaceuticals, from preclinical through to clinical trials and commercial supply and currently exports over 85% of its services from its facilities based in the UK and Sweden.

Cobra’s UK based GMP approved facility is a globally recognised centre of excellence for the development and production of biological material to support both gene- and immuno-therapy. In April 2017, Cobra announced a £15 million gene therapy expansion plan, to meet the increased demand from both plasmid DNA and viral vectors for Phase III and Commercial supply to support both existing and new customer requirements in the development of revolutionary disease therapies.

Peter Coleman, Chief Executive of Cobra Biologics, commented: “I am immensely proud of what Cobra has achieved over the last few years, culminating in the Queen’s Award. International Trade is vitally important for Cobra and the work that we do is challenging and requires a committed work force whose skills and dedication attract business from all over the world. I would like also to thank the Office for Life Science, Innovate UK and the Department for International Trade for their support of our expansion plans in the UK.”
Advertisement